Counteracting Effects Operating on Src Homology 2 Domain-containing Protein-tyrosine Phosphatase 2 (SHP2) Function Drive Selection of the Recurrent Y62D and Y63C Substitutions in Noonan Syndrome*♦
暂无分享,去创建一个
Gianni Cesareni | Luisa Castagnoli | Antonio Palleschi | Paola Torreri | Gianfranco Bocchinfuso | Bruce D. Gelb | Lorenzo Stella | L. Castagnoli | G. Cesareni | B. Gelb | M. Tartaglia | A. Palleschi | G. Bocchinfuso | L. Stella | S. Martinelli | Marco Tartaglia | E. Flex | Simone Martinelli | Elisabetta Flex | P. Torreri | Aurelio P. Nardozza | Silvia Delle Vigne | Gilda Sabetta | Serenella Venanzi | A. Nardozza | S. Venanzi | Silvia Delle Vigne | G. Sabetta
[1] B. Gelb,et al. Disorders of dysregulated signal traffic through the RAS‐MAPK pathway: phenotypic spectrum and molecular mechanisms , 2010, Annals of the New York Academy of Sciences.
[2] Carsten Kutzner,et al. GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.
[3] Kai Hilpert,et al. Peptide arrays on cellulose support: SPOT synthesis, a time and cost efficient method for synthesis of large numbers of peptides in a parallel and addressable fashion , 2007, Nature Protocols.
[4] Berk Hess,et al. LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..
[5] L. Castagnoli,et al. Tumor Suppressor Density-enhanced Phosphatase-1 (DEP-1) Inhibits the RAS Pathway by Direct Dephosphorylation of ERK1/2 Kinases* , 2009, The Journal of Biological Chemistry.
[6] S. Shoelson,et al. Crystal Structure of the Tyrosine Phosphatase SHP-2 , 1998, Cell.
[7] Malcolm McGregor,et al. Diverse Biochemical Properties of Shp2 Mutants , 2005, Journal of Biological Chemistry.
[8] J. Naismith,et al. Crystal structure of the tyrosine phosphatase Cps4B from Steptococcus pneumoniae TIGR4 in complex with phosphate. , 2009 .
[9] D. Barford,et al. PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects* , 2006, Journal of Biological Chemistry.
[10] H. Berendsen,et al. Molecular dynamics with coupling to an external bath , 1984 .
[11] B. Neel,et al. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. , 2003, Trends in biochemical sciences.
[12] M. Tartaglia,et al. Somatic PTPN11 mutations in childhood acute myeloid leukaemia , 2005, British journal of haematology.
[13] Jie Wu,et al. Noonan syndrome–associated SHP2/PTPN11 mutants cause EGF‐dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation , 2004, Human mutation.
[14] G D'Hont,et al. [The Noonan syndrome]. , 1982, Acta oto-rhino-laryngologica Belgica.
[15] N. Guex,et al. SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.
[16] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[17] B. Gelb,et al. Noonan syndrome and clinically related disorders. , 2011, Best practice & research. Clinical endocrinology & metabolism.
[18] Vladimir Vacic,et al. Two Sample Logo: a graphical representation of the differences between two sets of sequence alignments , 2006, Bioinform..
[19] J. Kuriyan,et al. Crystal structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase. , 1994, Structure.
[20] Menggang Yu,et al. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. , 2005, Blood.
[21] Bruce D Gelb,et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. , 2002, American journal of human genetics.
[22] M. Ahmadian,et al. Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation. , 2010, Human molecular genetics.
[23] Anne-Sophie Wavreille,et al. Alternative mode of binding to phosphotyrosyl peptides by Src homology-2 domains. , 2005, Biochemistry.
[24] B. Gelb,et al. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. , 2004, Blood.
[25] Nikolaj Blom,et al. Phospho.ELM: A database of experimentally verified phosphorylation sites in eukaryotic proteins , 2004, BMC Bioinformatics.
[26] N. Blom,et al. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. , 1999, Journal of molecular biology.
[27] Michael A. Patton,et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.
[28] S. Orkin,et al. A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development , 1997, Molecular and cellular biology.
[29] R. Foà,et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. , 2006, American journal of human genetics.
[30] M. Loh,et al. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. , 2004, Blood.
[31] Mohammad Reza Ahmadian,et al. Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders , 2011, Human mutation.
[32] T. Pawson,et al. SH2 domains recognize specific phosphopeptide sequences , 1993, Cell.
[33] B. Neel,et al. Activated Mutants of SHP-2 Preferentially Induce Elongation of Xenopus Animal Caps , 2000, Molecular and Cellular Biology.
[34] Junguk Park,et al. Decoding protein-protein interactions through combinatorial chemistry: sequence specificity of SHP-1, SHP-2, and SHIP SH2 domains. , 2005, Biochemistry.
[35] M. Tartaglia,et al. Structural and functional effects of disease‐causing amino acid substitutions affecting residues Ala72 and Glu76 of the protein tyrosine phosphatase SHP‐2 , 2006, Proteins.
[36] M. Billeter,et al. MOLMOL: a program for display and analysis of macromolecular structures. , 1996, Journal of molecular graphics.
[37] F. Jirik,et al. Characterization of protein tyrosine phosphatase SH-PTP2. Study of phosphopeptide substrates and possible regulatory role of SH2 domains. , 1994, The Journal of biological chemistry.
[38] P. Kollman,et al. Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models , 1992 .
[39] M. Vidaud,et al. Reduced phosphatase activity of SHP‐2 in LEOPARD syndrome: Consequences for PI3K binding on Gab1 , 2006, FEBS letters.
[40] H. Berendsen,et al. Interaction Models for Water in Relation to Protein Hydration , 1981 .
[41] L. Castagnoli,et al. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. , 2008, Human molecular genetics.
[42] S. Harrison,et al. Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2 , 1996, Nature.
[43] J. Licht,et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.
[44] Nathan A. Baker,et al. Electrostatics of nanosystems: Application to microtubules and the ribosome , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[45] L. Blieden,et al. [Leopard syndrome]. , 1983, Harefuah.
[46] T. Pawson,et al. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp‐2 , 1997, The EMBO journal.
[47] Alexander D. MacKerell,et al. Tyr66 acts as a conformational switch in the closed-to-open transition of the SHP-2 N-SH2-domain phosphotyrosine-peptide binding cleft , 2007, BMC Structural Biology.